Clinical trials: Endocrine, Nutritional, Metabolic and Immunity Disorders
Type 1 Diabetes Mellitus
The Effect of Uric Acid Lowering in Type 1 Diabetes
Patients with type 1 diabetes mellitus (T1DM) are at high risk of developing kidney complications potentially leading to end stage renal disease.
- Trial name
- NCT02344602
- Testing
- Febuxostat
- Where
- Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Type 1 Diabetes
Effects of Metreleptin in Type 1 Diabetes Mellitus
This study will add leptin therapy to the current insulin therapy of Type 1 Diabetics with the aim of lowering the total insulin requirements and suppressing the steep fluctuations typically associated with Type 1 Diabetes.
- Trial name
- NCT01268644
- Testing
- Leptin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 1
Study to Evaluate Safety and Efficacy of IBsolvMIR in Islet Transplantation
This is a Phase II open, randomized, active comparator-controlled multi center study in patients with severe type-1 diabetes. This is a two-armed study where patients are randomized in a 2:1 ratio between IBsolvMIR and heparin.
- Trial name
- NCT03867851
- Testing
- IBsolvMIR, Heparin
- Where
- 5 sites in Netherlands, Norway and 1 more
- Volunteers
- 7 people
- Sponsor
- TikoMed AB
Diabetes Mellitus, Type 1
Comprehensive Care in Type 1 Diabetes and Associated Outcomes
Quasi-experimental, retrospective, before and after study, with a control group, to evaluate the effect of an intervention based on disease management, on metabolic control and hospitalizations, in a group of patients with type…
- Trial name
- AIDDA (NCT03835195)
- Testing
- Diabetes Disease Management Program, Usual Care Process
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Universidad de Antioquia
Type 1 Diabetes
Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes
Type 1 diabetes (T1D) is the most common severe autoimmune disease worldwide and is caused by the body's immune destruction of its own insulin producing pancreatic beta cells leading to insulin deficiency and development of…
- Trial name
- DILfrequency (NCT02265809)
- Testing
- Aldesleukin
- Where
- United Kingdom
- Volunteers
- 41 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Type 1 Diabetes
Assessment of a Decision Support Tool in Participants With Type 1 Diabetes
Type 1 diabetes (T1D) is a complex disease with a high risk of both hyper- and hypoglycemia which can lead to severe acute and chronic complications.
- Trial name
- NCT04428645
- Testing
- DailyDose Decision Support
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Stroke, Acute, Hyperglycemia
Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke
Study objective is to determine whether Pioglitazone (PGZ) can improve clinical outcomes in hyperglycemic acute ischemic stroke (IS).
- Conditions
- Stroke, Acute, Hyperglycemia, Diabetes
- Trial name
- NCT04123067
- Testing
- Pioglitazone 45 mg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Milton S. Hershey Medical Center
Type 1 Diabetes
A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
VC01-103 will evaluate an experimental combination product, cell replacement therapy intended to provide a functional cure to subjects with Type 1 Diabetes.
- Trial name
- VC01-103 (NCT04678557)
- Testing
- VC-01 Combination Product
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- ViaCyte
Coping Behavior, Emotional Distress
Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care
The Creative Arts Diabetes Initiative will offer facilitated art therapy with a group/peer-support environment to two groups of youth/young adults, one with type 1 diabetes, and one with type 2 diabetes.
- Conditions
- Coping Behavior, Emotional Distress, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- CADI (NCT02790892)
- Testing
- Art therapy - pre and post test measures
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Manitoba
Type 1 Diabetes Mellitus
Safety and Efficacy Study of Encapsulated Human Islets Allotransplantation to Treat Type 1 Diabetes
In view to avoid immunosuppression, the investigators are submitting a Phase 1 clinical trial protocol testing the safety and the efficacy of encapsulated human islets in a "Monolayer Cellular Device" for allogeneic islets…
- Trial name
- NCT00790257
- Testing
- Encapsulated human islets in a "Monolayer Cellular Device"
- Where
- Belgium
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Type 1 Diabetes
Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation
The purpose of this study is to test the meal anticipation module on a closed loop algorithm, assessing efficacy and safety.
- Trial name
- NCT04877730
- Testing
- Fully Closed Loop (FCL), Fully Closed Loop with meal anticipation module (FCL+), Hybrid Closed Loop (HCL)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Virginia
Stress, Type 1 Diabetes
Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)
Study hypothesis: Waking up in response to an alarm clock may evoke a stress reaction that leads to rising glucose concentrations.
- Trial name
- NCT00740012
- Testing
- Continuous glucose monitoring, alarm- clock intervention, patient perform blood glucose self monitoring, nurse intervention
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
Type 1 Diabetes, Type 2 Diabetes
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1.
- Trial name
- NCT06976619
- Testing
- Liraglutide Pen Injector, Saline Injections
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapid®) with an external…
- Trial name
- onset® 4 (NCT01999322)
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- 2 sites in United States, Germany
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp
Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's…
- Trial name
- NCT02189694
- Testing
- Single-hormone closed-loop strategy, Dual-hormone closed-loop strategy, Insulin pump therapy
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant…
- Conditions
- Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias
- Trial name
- HSCT+RIC (NCT01962415)
- Testing
- Hydroxyurea, Alemtuzumab, Fludarabine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Paul Szabolcs
Diabetes Mellitus, Type 1
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants…
- Trial name
- NCT05184868
- Testing
- AT247, NovoLog, Fiasp
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arecor Limited
Type 1 Diabetes, Type 2 Diabetes
Feasibility Study - Integrated Sensor and Infusion Set. Trial III
The purpose of this study is to collect performance data on the Integrated sensor and infusion set during 3 days of use and demonstrate performance adequacy of the integrated sensor and infusion set with glucose sensing and…
- Trial name
- NCT01773668
- Testing
- Integrated sensor and infusion set.
- Where
- Sweden
- Volunteers
- 17 people
- Sponsor
- Medtronic Diabetes R&D Denmark
Type 1 Diabetes Mellitus
Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes
This overall research goal will be to develop a mobile-based module to improve glycemic control during the menstrual cycle in women with Type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01653210
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Pilot Study of Remote Glucose Monitoring Among Pediatric Patients With Type 1 Diabetes
This project explores the feasibility and utility of remote glucose monitoring for a cohort of children and adolescents with type 1 diabetes (T1D) cared for at UC Davis Health (UCDH).
- Trial name
- NCT04696640
- Testing
- Remote Patient Monitoring
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.